Angiogenesis factor pattern differs in acute lymphoblastic leukemia and chronic lymphocytic leukemia
- 1 August 2007
- journal article
- research article
- Published by Taylor & Francis in Hematology
- Vol. 12 (4) , 319-324
Abstract
Angiogenesis is an important event in the survival and progression of solid tumors. The angiogenic status and the exact role of the angiogenic cytokines in lymphoid leukemia has not been fully elucidated. We have investigated the profile of the systemic components of angiogenic regulation in B-lineage acute lymphoblastic leukemia (B-ALL) and B-chronic lymphocytic leukemia (B-CLL), namely vascular endothelial growth factor (VEGF), tumor necrosis factor-alpha (TNF-α), endostatin and matrix metalloproteinase-9 (MMP-9) using enzyme-linked immunosorbent assay (ELISA). In B-ALL patients, sVEGF, and MMP-9 were significantly lower than control levels at diagnosis (p < 0.001) and increased to near control levels in remission (p > 0.05). Both serum TNF-α and endostatin levels showed no significant difference at diagnosis (p > 0.05) and in remission (p > 0.05) compared to control levels. VEGF, TNF-α, MMP-9 and endostatin levels were not significantly correlated with peripheral white cell count or bone marrow blast cell count, but were positively correlated with platelet count. In B-CLL patients, serum VEGF, MMP-9 and TNF-α were significantly higher (p < 0.001 = 0.009, 0.007, respectively) and decreased to near control levels in remission (p > 0.05 for all). Serum endostatin levels showed no significant difference at diagnosis and in remission compared to control levels (p > 0.05). A significant positive correlation between VEGF, TNF-α, MMP-9 and peripheral white cell counts, bone marrow lymphocytic count and platelets count were found. In conclusion, our data suggest that the driving forces of angiogenic factors (VEGF, TNF-α and MMP-9) in adult B-ALL appears different from that in B-CLL patients.Keywords
This publication has 11 references indexed in Scilit:
- Serum angiogenin is not elevated in patients with early B‐cell chronic lymphocytic leukemia but is prognostic factor for disease progressionEuropean Journal of Haematology, 2004
- The role of matrix metalloproteinase 9 in the pathogenesis of chronic lymphocytic leukaemiaBritish Journal of Haematology, 2004
- Metastasis and Angiogenesis2004
- Marrow matrix metalloproteinases (MMPs) and tissue inhibitors of MMP in acute leukaemia: potential role of MMP‐9 as a surrogate marker to monitor leukaemic status in patients with acute myelogenous leukaemiaBritish Journal of Haematology, 2002
- B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic moleculesLeukemia, 2002
- Production of matrix metalloproteinase-9 in early stage B-CLL: suppression by interferonsLeukemia, 2002
- Angiogenesis is increased in B-cell chronic lymphocytic leukemiaBlood, 2001
- Clinical Importance of Serum Vascular Endothelial and Basic Fibroblast Growth Factors in Children with Acute Lymphoblastic LeukemiaLeukemia & Lymphoma, 2001
- INTRINSIC CAPACITY OF MONOCYTES TO PRODUCE CYTOKINES EX VIVO IN PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKAEMIACytokine, 2000
- Infiltrative capacity of T leukemia cell lines: A distinct functional property coupled to expression of matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of metalloproteinases-1 (TIMP-1)Clinical & Experimental Metastasis, 1999